2023年6月8日

加州山景城——(業務線)——醫生生命科學(“醫生”),矽穀生物技術創業公司,今天宣布它進入了科研合作與百時美施貴寶公司(NYSE: BMY)。在協作,醫生利用其可伸縮的腫瘤三維模型執行CRISPR屏幕功能基因組學在實體瘤百時美施貴寶公司感興趣的跡象。醫生也利用其免疫細胞和腫瘤細胞培養平台,確定新的基因相關免疫細胞殺死癌細胞。“我們非常激動,百時美施貴寶公司選擇醫生作為一個合作者來推進其腫瘤發現項目,“Kyuho漢說,博士,醫師的聯合創始人和首席執行官。“我們期待與百時美施貴寶公司識別小說腫瘤學目標推進潛在有效的新藥物對癌症患者。“在協議的條款下,醫生會收到預付款的科研合作和有資格獲得額外選項target-by-target基礎上支付。醫生也符合未來發展和監管的裏程碑付款。醫生已經開發了一個專有CRISPR功能基因組學平台,采用patient-tumor-like癌症模型來確定最優目標和癌症生物標記基因。雖然功能基因組學方法已經廣泛用於屏幕全基因組基因功能的癌症,醫生首次表明,使用三維腫瘤模型,而不是傳統的二維文化,可以大大改善的準確性和可譯性CRISPR功能基因組學。使用這種技術,醫生可以確定新的癌症目標和生物標記發展藥物固體腫瘤的跡象。 MEDiC’s unique approach has already attracted partners seeking novel targets for drug development. About MEDiC Life Sciences MEDiC Life Sciences uses CRISPR functional genomics to discover new therapeutic targets and biomarkers for solid cancers. The company is developing internal drug programs for hepatocellular carcinoma and triple negative breast cancer, while delivering novel targets/biomarkers for other solid tumor indications pursued by its partners' oncology programs. Founded in 2020, MEDiC originated from discoveries advanced through the SPARK program at Stanford University. MEDiC has secured backing from a group of investors including TOP Harvest Capital, Primer Sazze Partners, Illumina Accelerator, Big Basin Capital, and First In Ventures. To learn more about MEDiC, visit their website at www.medicls.com View source version on businesswire.com: https://www.businesswire.com/news/home/20230605005591/en/ Copyright Business Wire 2023